{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=XOLAIR%C2%AE+Injection",
    "query": {
      "intervention": "XOLAIR® Injection"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-17T22:24:06.964Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07059091",
      "title": "Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)",
        "Allergies"
      ],
      "interventions": [
        {
          "name": "Omalizumab (Xolair®)",
          "type": "DRUG"
        },
        {
          "name": "Sodium Chloride (NaCl) 0.9 %",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 334,
      "start_date": "2026-02-12",
      "completion_date": "2031-05",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-09-17T22:24:06.964Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07059091"
    },
    {
      "nct_id": "NCT05774639",
      "title": "Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Idiopathic Urticaria"
      ],
      "interventions": [
        {
          "name": "Omalizumab Injection",
          "type": "DRUG"
        },
        {
          "name": "Xolair Prefilled Syringe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kashiv BioSciences, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 600,
      "start_date": "2023-08-15",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-02-05",
      "last_synced_at": "2026-09-17T22:24:06.964Z",
      "location_count": 4,
      "location_summary": "Brandon, Florida • Brooksville, Florida • Miami Lakes, Florida + 1 more",
      "locations": [
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "West Lafayette",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05774639"
    },
    {
      "nct_id": "NCT00377572",
      "title": "Inner-City Anti-IgE Therapy for Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "omalizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "omalizumab placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "6 Years to 20 Years"
      },
      "enrollment_count": 419,
      "start_date": "2006-10",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2017-03-21",
      "last_synced_at": "2026-09-17T22:24:06.964Z",
      "location_count": 8,
      "location_summary": "Tucson, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 5 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00377572"
    },
    {
      "nct_id": "NCT01157117",
      "title": "OIT and Xolair® (Omalizumab) in Cow's Milk Allergy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Milk Allergy"
      ],
      "interventions": [
        {
          "name": "Placebo for omalizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Omalizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Milk powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Hugh A Sampson, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "7 Years to 35 Years"
      },
      "enrollment_count": 77,
      "start_date": "2010-08",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2020-08-14",
      "last_synced_at": "2026-09-17T22:24:06.964Z",
      "location_count": 3,
      "location_summary": "Stanford, California • Baltimore, Maryland • New York, New York",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01157117"
    },
    {
      "nct_id": "NCT03881696",
      "title": "Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Peanut Allergy",
        "Multi-food Allergy"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Omalizumab",
          "type": "DRUG"
        },
        {
          "name": "Multi-Allergen Oral Immunotherapy",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Multi-Allergen Oral Immunotherapy",
          "type": "DRUG"
        },
        {
          "name": "Double-Blind Placebo-Controlled Food Challenge Based Treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "1 Year to 55 Years"
      },
      "enrollment_count": 471,
      "start_date": "2019-07-22",
      "completion_date": "2025-07-01",
      "has_results": true,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-09-17T22:24:06.964Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03881696"
    },
    {
      "nct_id": "NCT01430403",
      "title": "Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Inhaled Corticosteroid Boost Therapy (ICS)",
          "type": "DRUG"
        },
        {
          "name": "Placebo omalizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo fluticasone",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 478,
      "start_date": "2011-09",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-09-17T22:24:06.964Z",
      "location_count": 8,
      "location_summary": "Denver, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01430403"
    },
    {
      "nct_id": "NCT02814630",
      "title": "Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Idiopathic Urticaria"
      ],
      "interventions": [
        {
          "name": "Xolair",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Asthma Inc Clinical Research Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2016-09",
      "completion_date": "2018-11-02",
      "has_results": false,
      "last_update_posted_date": "2019-01-24",
      "last_synced_at": "2026-09-17T22:24:06.964Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02814630"
    },
    {
      "nct_id": "NCT04976192",
      "title": "Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Urticaria"
      ],
      "interventions": [
        {
          "name": "TEV-45779",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "XOLAIR® Injection",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 608,
      "start_date": "2021-08-30",
      "completion_date": "2024-04-05",
      "has_results": true,
      "last_update_posted_date": "2025-10-07",
      "last_synced_at": "2026-09-17T22:24:06.964Z",
      "location_count": 9,
      "location_summary": "Bakersfield, California • Clearwater, Florida • Coral Gables, Florida + 6 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04976192"
    }
  ]
}